Form 4: Crinetics Pharmaceuticals Executive Dana Pizzuti Reports Stock Transactions

Dana Pizzuti, Chief Medical and Development Officer at Crinetics Pharmaceuticals, reports the exercise of stock options and subsequent sale of shares on June 24, 2024.

Summary

• On June 24, 2024, Dana Pizzuti, the Chief Medical and Development Officer of Crinetics Pharmaceuticals, exercised stock options to acquire 9,500 shares of common stock at a price of $16.89 per share.
• Simultaneously, Pizzuti sold 9,500 shares of common stock in open market transactions at a volume weighted average price of $45.73 per share, with prices ranging from $45.53 to $45.88.
• Following these transactions, Pizzuti directly owns 27,786 shares of Crinetics Pharmaceuticals common stock.
• Pizzuti also holds options to purchase 167,792 shares of common stock.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock transactions by an executive. The sentiment is neutral as it doesn't inherently indicate positive or negative views on the company's future.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• Shareholders may interpret the transactions as a signal of the executive's view on the company's stock value.
• The transactions have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates